215437-36-8

Basic information

• Product Name: 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2-methoxymethyl-6-methyl-pyrimidin-5-yl)-ethanone
• Synonyms: 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2-methoxymethyl-6-methyl-pyrimidin-5-yl)-ethanone
• CAS NO: 215437-36-8
• Molecular Weight: 485.589
• Mol File: 215437-36-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2-methoxymethyl-6-methyl-pyrimidin-5-yl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2-methoxymethyl-6-methyl-pyrimidin-5-yl)-ethanone(215437-36-8)
• EPA Substance Registry System: 1-(4-{[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-2-methoxymethyl-6-methyl-pyrimidin-5-yl)-ethanone(215437-36-8)

Safety Data

• Hazardous Substances Data: 215437-36-8(Hazardous Substances Data)

Upstream product

• 215437-33-5 C-[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-yl]-methylamine 
• 215437-32-4 2-methoxymethyl-4-chloro-5-(1-ethoxyvinyl)-6-methylpyrimidine 
• 215437-31-3 4-chloro-5-iodo-2-(methoxymethyl)-6-methylpyrimidine 
• 215437-30-2 5-iodo-2-(methoxymethyl)-6-methylpyrimidin-4(3H)-one 
• 3122-74-5 2-(methoxymethyl)-6-methylpyrimidin-4(3H)-one 
• 215437-35-7 [2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[5-(1-ethoxy-vinyl)-2-methoxymethyl-6-methyl-pyrimidin-4-yl]-amine 

Downstream Products

• 215437-38-0 8-[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5-hydroxy-2-hydroxymethyl-4-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 215437-37-9 8-[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-5-hydroxy-2-methoxymethyl-4-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant articles and documents

Metabolites of the angiotensin II antagonist tasosartan: The importance of a second acidic group

Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT1 receptor binding.